Digital platform for U.S. healthcare professionals
Key Finding: Doximity operates the largest verified network of U.S. clinicians (over 3 million members), delivering consistent double-digit revenue growth (FY2026 revenue $644.9M, +13% YoY) through subscription-based tools for networking, clinical information, telehealth, and careers, while navigating intensifying AI competition and mixed analyst sentiment.
Company Overview & History
Overview (Facts)
Core product: Doximity platform — personalized newsfeed with clinical articles, peer updates, discussions, sponsored content from pharma/health systems; plus telehealth, collaboration, on-call scheduling (Amion), digital fax, e-prescribing, and career tools.
Revenue model: Primarily subscription revenue from Marketing Solutions (pharma/health systems), Hiring Solutions, and Workflow tools.
Headquarters: San Francisco, CA; ~880 employees.
Mission: Help clinicians be more productive to provide better patient care.
52-week range (as of early Aug 2026 data): Approximately $17.15 – $76.51.
Annual performance examples (calendar years, approximate closing prices): 2024 ~+90%, 2025 ~-17%, 2026 YTD mixed/volatile with significant swings around earnings.
Interpretation: Stock has shown high volatility typical of growth tech/healthtech names, with strong post-IPO gains followed by corrections; recent years reflect broader market and sector pressures.
Data Limitation: Historical performance data is sourced from aggregated market reports as of searches in August 2026. Exact daily/weekly returns vary; consult full charts on Yahoo Finance or company IR for precise timelines. No current price is displayed per guidelines.
Financial Highlights (Facts from Company Releases)
Metric
FY2026 (ended ~Mar 2026)
FY2025 (ended ~Mar 2025)
YoY Change
Total Revenue
$644.9 million
$570.4 million
+13%
Net Income
$196.1 million
$223.2 million
-12%
Non-GAAP Net Income
$302.7 million
$286.1 million
+6%
Operating Cash Flow
$326.5 million
~ prior year lower
+19%
Free Cash Flow
$317.5 million
—
Strong
Q4 FY2026 (Fact): Revenue $145.4M (+5% YoY); Net income $19.1M (margin 13.1%).
Assumptions & Limitations: Financial figures are primarily from company earnings releases (FY2026 ended March 31, 2026). Subscription revenue is the dominant segment. Growth rates and margins are GAAP unless noted. Future performance depends on user engagement, AI feature adoption, and macroeconomic factors in healthcare. Data is not forward-looking.
Analyst Ratings
Consensus Summary (as of recent 2026 data)
Overall Consensus
Hold / Moderate Buy (varies by source)
Buy / Strong Buy
~30-40% of analysts
Hold
~50-55%
Sell
~5-10%
Average Price Target
$24.65 – $29.33 (range: $18 low to $65 high)
Recent Activity (Interpretation): Multiple target raises (e.g., Needham to $41, Raymond James to $38, Evercore to $40) following earnings, citing AI momentum and physician engagement. Some downgrades or reiterations to Sell/Hold due to competition (e.g., OpenEvidence) and margin pressures from AI investments.
Notable Recent Notes
Positive: AI search momentum, rising engagement, value-based care partnerships.
Negative/Cautious: AI investment headwinds, competition in clinical decision support.
Uncertainties: Ratings and targets fluctuate frequently post-earnings; long-term AI differentiation vs. competitors remains unproven. Analyst views are opinions, not guarantees.
Data Limitation: Analyst coverage and targets are snapshots from multiple sources (TipRanks, MarketBeat, etc.) as of August 2026 searches. Consensus and individual ratings change rapidly; always verify latest reports directly from firms.
Customers & Competitors
Customers (Facts)
Primary users: Over 3 million verified U.S. clinicians (physicians, other healthcare professionals) across specialties.
Paying customers: Pharmaceutical manufacturers and health systems using Marketing Solutions (sponsored content), Hiring Solutions (talent acquisition), and Workflow tools.
Recent: Partnership with Aledade (value-based care enablement) to bring clinical AI tools to primary care physicians.
Interpretation: Strong network effects from large clinician base drive value for B2B customers in pharma and health systems.
Competitors (Facts)
Category
Examples
Professional Networking / Health IT
H1, Tebra, Practice Better, Waystar
Telehealth / Workflow
Teladoc Health (TDOC), others
Clinical AI / Decision Support
OpenEvidence (direct competitor with ongoing lawsuits), Vera Health, Glass Health, UpToDate (Wolters Kluwer), Pathway Medical (acquired by Doximity)
Other
Certara, Heartflow, Schrodinger
Uncertainties: AI clinical tools market is rapidly evolving with new entrants; lawsuits between Doximity and OpenEvidence (allegations of prompt injection/reverse engineering) highlight competitive intensity.
Overall Data Limitations & Assumptions: All information compiled from public web sources (company IR, Yahoo Finance, Wikipedia, analyst aggregators) as of searches conducted on/around August 7, 2026. Financials reflect reported periods ending March 2026; stock performance is historical. Analyst data and news are time-sensitive. This is for informational purposes only — not investment advice. Verify all data with primary sources before making decisions. No current stock price or real-time quotes are included.